Seminars in Hematology
Volume 40, Issue 4 , Pages 308-320 , October 2003

Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling

  • Fenghuang Zhan

      Affiliations

    • Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    • ,
  • Bart Barlogie

      Affiliations

    • Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    • ,
  • John Shaughnessy Jr

      Affiliations

    • Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    • Corresponding Author InformationAddress correspondence to John Shaughnessy Jr, PhD, Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, University of Arkansas for Medial Sciences, 4301 W Markham St, Mail Slot 706, Little Rock, AR 72205, USA

References 

  1. Alizadeh AA, Eisen MB, Davis RE. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  2. Barlogie B, Shaughnessy J, Munshi N, et al.  Plasma cell myeloma. In:  Beutler E,  Lichtman M,  Coller B, et al. editor. Hematology. William’s Hematology. (ed 6).. New York, NY: McGraw-Hill; 2001;
  3. Calin GA, Dumitru CD, Shimizu M, et al.  Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524–15529
  4. Flactif M, Zandecki M, Lai JL, et al.  Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia. 1995;9:2109–2114
  5. Ge N-L, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood. 2000;96:2856–2861
  6. Georgii-Hemming P, Wiklund HJ, Ljunggren O, et al.  Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood. 1996;88:2250–2258
  7. Goss KH, Risinger MA, Kordich JJ, et al.  Enhanced tumor formation in mice heterozygous for Blm mutation. Science. 2002;297:2051–2053
  8. Gruber SB, Ellis NA, Scott KK, et al.  BLM heterozygosity and the risk of colorectal cancer. Science. 2002;297:2013
  9. Jacobson J, Zhan F, Sawyer J, et al.  Gene expression reflects changes in ploidy of some, but not all chromosomes, in multiple myeloma. Blood. 2002;100(suppl 1):1225a; abstr
  10. Kuehl WM, Bergsagel PL. Multiple myeloma (Evolving genetic events and host interactions). Nature Rev Cancer. 2002;2:175–187
  11. Kyle RA, Therneau TM, Rajkumar SV, et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–569
  12. Latreille J, Barlogie B, Dosik G, et al.  Cellular DNA content as a marker of human multiple myeloma. Blood. 1980;55:403–408
  13. Lin H, Liu XY, Subramanian B, et al.  Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination. Int J Cancer. 2002;97:121–128
  14. Mabuchi H, Fujii H, Calin G, et al.  Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res. 2001;61:2870–2877
  15. McSweeney PA, Wells DA, Shults KE, et al.  Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. Blood. 1996;88:622–632
  16. Medina F, Segundo C, Campos-Caro A, et al.  The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood. 2002;99:2154–2161
  17. Mertens D, Wolf S, Schroeter P, et al.  Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood. 2002;99:4116–4121
  18. Migliazza A, Bosch F, Komatsu H, et al.  Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood. 2001;97:2098–2104
  19. Munshi N, Tricot G, Barlogie B. Plasma cell neoplasms. In:  DeVita VT,  Hellman S,  Rosenberg S editor. Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 2465–2499
  20. Qiang Y-W, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma (Downstream elements, functional correlates, and pathway cross-talk). Blood. 2002;99:4138–4146
  21. San Miguel JF, Garcia-Sanz R, Gonzalez M, et al.  Immunophenotype and DNA cell content in myeloma. Baillieres Clin Haematol. 1995;8:735–759
  22. Santra M, Zhan F, Tian E, et al.  A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lack FGFR3 expression but maintain an IGH/mmset fusion transcript. Blood. 2003;101:2374–2376
  23. Shaughnessy J, Gabrea A, Qi Y, et al.  Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood. 2001;98:217–223
  24. Shaughnessy J, Barlogie B, Zhan F, et al.  Continuous absence of metaphase abnormalities especially of chromosome 13 and hypodiploidy assures long term survival in multiple myeloma treated with Total Therapy I (Interpreted in the context of gene expression profiling). Blood. 2003;102:592–600
  25. Shaughnessy J, Tian E, Sawyer J, et al.  Prognostic impact of cytogenetic and interphase FISH defined chromosome 13 deletion in multiple myeloma (Early results of total therapy II). Br J Haematol. 2003;120:44–52
  26. Shaughnessy J, Tian E, Sawyer J, et al.  High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000;96:1505–1511
  27. Shaughnessy J, Zhan F, McCastlain K, et al.  Gene expression profiling in the prediction of response of multiple myeloma to the proteasome inhibitor PS-341. Blood. 2002;100(suppl 1):1512a; abstr
  28. Standal T, Borset M, Lenhoff S, et al.  Serum insulin like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood. 2002;100:3925–3929
  29. Tarte K, De Vos J, Thykjaer T, et al.  Generation of polyclonal plasmablasts from peripheral blood B cells (a normal counterpart of malignant plasmablasts). Blood. 2002;100:1113–1122
  30. Tarte K, De Vos J, Zhan F, et al: : Gene expression profiling of plasma cells and plasmablasts: Toward a better understanding of the late stages of B-cell differentiation, Blood (submitted)
  31. Townsley F, Aristarkhov A, Beck S, et al.  Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci USA. 1997;94:2362–2367
  32. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116–5121
  33. Zhan F, Hardin J, Kordsmeier B, et al.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745–1757
  34. Zhan F, Tian E, Bumm K, et al.  Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late stage B-cell development. Blood. 2003;101:1128–1140
  35. Zhan F, Walker R, Santra M, et al.  Gene expression profiles can identify known and suspected multiple myeloma associated 14q32 translocations. Blood. 2002;100(suppl 1):1190a; abstr

PII: S0037-1963(03)00197-5

doi: 10.1016/S0037-1963(03)00197-5

Seminars in Hematology
Volume 40, Issue 4 , Pages 308-320 , October 2003

Article Tools

* Image Usage & Resolution